作者:Lingjian Zhu、Zhenyuan Miao、Chunquan Sheng、Wei Guo、Jianzhong Yao、Wenfeng Liu、Xiaoying Che、Wenya Wang、Pengfei Cheng、Wannian Zhang
DOI:10.1016/j.ejmech.2010.02.051
日期:2010.7
The homocamptothecin (hCPT) represents a new class of topoisomerase inhibitor which combines enhanced plasma stability and strong antitumor activity. Fluorine imparts desirable characteristics to drugs by modulating both the pharmacokinetics and pharmacodynamic properties of a drug. Therefore, in an attempt to improve the antitumor activity of homocamptothecins, seven new 7-trifluoromethylated homocamptothecin
同型喜树碱(hCPT)代表一类新的拓扑异构酶抑制剂,它具有增强的血浆稳定性和强大的抗肿瘤活性。氟通过调节药物的药代动力学和药效学性质赋予药物所需的特性。因此,为了提高同型喜树碱的抗肿瘤活性,通过脯氨酸催化的弗里德兰德法制备了七个新的7-三氟甲基化的同型喜树碱衍生物。评价了在体内和体外对癌细胞系的抗肿瘤活性,以及拓扑异构酶I介导的化合物6c和8b的DNA切割的抑制特性。这些三氟甲基化的hCPT衍生物中的几种(例如6a,6b和6c)具有比拓扑替康(TPT)更高的体外抗肿瘤活性。特别地,化合物6c显示出与TPT相当的有效体内抗肿瘤活性。